DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients-Reference-Cited by-同舟云学术

DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients

Published:2004-01 Issue:4 Volume:63 Page:684-687
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Altundag Ozden,Altundag Kadri,Gunduz Mehmet

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases;Beatson;Lancet,1896

2. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer;Iwase;Cancer Chemother. Pharmacol.,2003

3. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study;Eiermann;Ann. Oncol.,2001

4. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling;Clarke;Oncogene,2003

5. Steroid hormone receptors in breast cancer management;Osborne;Breast Cancer Res. Treat.,1998

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications;Frontiers in Bioscience-Landmark;2024-08-19

2. Crosstalk of methylation and tamoxifen in breast cancer (Review);Molecular Medicine Reports;2024-08-09

3. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors;Advances in Cancer Research;2023

4. The role of estrogen receptor beta in breast cancer;Biomarker Research;2020-09-07

5. Antiproliferative activities of procainamide and its binding with calf thymus DNA through multi-spectroscopic and computational approaches;Journal of Molecular Liquids;2018-05